Aura Biosciences (AURA) Q2 2026 earnings summary

Executive summary

• Lead candidate bel-sar is in late-stage clinical development for early choroidal melanoma, with expansion into other ocular oncology indications and non-muscle invasive bladder cancer (NMIBC); Phase 3 Compass trial is fully enrolled with 108 patients, exceeding target, and topline data expected in H2 2027.

• Strategic focus has shifted to ocular oncology, deprioritizing NMIBC to concentrate resources, with increased investment in choroidal metastases and ocular surface cancer programs.

• Interim NMIBC data show 81% objective response at 3 months and up to 100% disease-free status at 9-12 months among evaluable patients.

• Organizational restructuring in August 2026 includes a 20% workforce reduction, new executive appointments, and extends cash runway into 1H 2029.

• Leadership team strengthened with new CEO, COO, Chief Regulatory and Quality Officer, and Chief People Officer.

Financial highlights

• Net loss for Q2 2026 was $45.6 million, up from $27.0 million in Q2 2025; six-month net loss was $79.3 million, up from $54.5 million year-over-year.

• Operating expenses for Q2 2026 were $48.1 million, up from $28.6 million in Q2 2025, driven by increased R&D and G&A costs.

• Cash, cash equivalents, and marketable securities totaled $323.8 million as of June 30, 2026.

• Raised $280.8 million net in May 2026 follow-on offering; $39.0 million used to repurchase 6.9 million shares.

• Total assets increased to $348.1 million as of June 30, 2026, from $169.4 million at December 31, 2025.

Outlook and guidance

• Cash runway expected to fund operations into the first half of 2029, supporting ongoing trials and potential commercialization.

• No revenue expected until at least after regulatory approval and commercialization of bel-sar.

• Expenses anticipated to increase as clinical programs advance and company prepares for commercialization.

• Topline data from the Phase 3 Compass trial expected in H2 2027; updates on additional ocular oncology programs anticipated in Q1 2027.